Cannabis Learning EDU

Alzheimer's Disease
Statistics on Alzheimer’s Disease:
More than 5 million Americans are living with Alzheimer’s. By 2050 this number could be as high as 16 million.
Every 66 Seconds someone in the United States develops the disease.
1 in 3 seniors dies with Alzheimer’s or another dementia. It is the 6th leading cause of death in the United States. It kills more than breast and prostate cancer combined.
(Source: Alzheimer’s Association, www.alz.org/facts)
US Patent 8673368, Mar 18, 2014 - Cannabinoid-containing plant extracts as neuroprotective agents
US Patent Filing US 6,630,507 B1 Cannabinoids as Antioxidants and Neuroprotectants
How Cannabinoids May Slow Brain Aging
Szalavitz, Maia
Time. 2012 Oct 29, (Full News article).
Cannabinoid Modulation of Neuroinflammatory Disorders
Saito, Viviane M., et al.
Current Neuropharmacology. 2012 Jun, 10(2): 159-166 (Full).
Terpenoids as Potential Anti-Alzheimer’s Disease Therapeutics
Yoo, Ki-Yeol, et al.
Molecules. 2012 Mar 12, 17(3): 3524-3528 (Full).
An Introduction to the Medical Benefits of Cannabis
Acton, Jeremy, et al.
NORML. 2011 Apr 4 (Full).
Alzheimer’s disease; taking the edge off with cannabinoids?
Campbell, VA, et al.
British Journal of Pharmacology. 2009 Jan 29, 152(5): 655-662 (Full).
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, Antonio Waldo
Revista Brasileira de Psiquiatria. 2008 Sep, 30(3) (Full).
A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Patholiogy
Eubanks, Lisa M., et al.
Molecular pharmaceutics. 2006, 3(6): 773-777 (Full).
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation
Ehrhart, Jared, et al.
Journal of Neuroinflammation. 2005 Dec 12, 2(29) (Full).
Ramirez, Belen G, et al.
The Journal of Neuroscience. 2005 Feb 23, 25(8): 1904-1913 (Full).
Iuvone, Teresa, et al.
Journal of Neurochemistry. 2004 Apr, 89(1): 134-141 (Full).
Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide
Facchinetti, Fabrizio, et al.
GLIA. 2003 Jan 15, 41(2): 161-168 (Full).
The therapeutic potential of the endocannabinoid system for Alzheimer’s disease
Karl, Tim, et al.
Expert Opinion on Therapeutic Targets. 2012 Apr, (abstract).
Martin-Moreno, Ana Maria, et al.
Molecular Pharmacology. 2011 Feb 24, (abstract).
Bisogno, Tiziana, et al.
CNS and Neurological Disorders: Drug Targets. 2010 Nov, 9(5): 564-573 (abstract).
Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimer’s Disease
Campillo, N.E., et al.
Mini Reviews in Medicinal Chemistry. 2009 May, (abstract).
The Role of the Endocannabinoid System in Alzheimer’s Disease: Facts and Hypothesis
Bosogno, Tiziana, et al.
Current Pharmaceutical Design. 2008 Aug, (abstract).
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
Fernandez-Ruiz, Javier, et al.
Trends in Pharmacological Sciences. 2007 Jan, (abstract).
A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Pathology
Eubanks, Lisa M, et al.
Molecular Pharmaceutics. 2006 Aug 9, 3(6): 773-777 (abstract).
Esposito, Giuseppe, et al.
Neuroscience Letters. 2006 May 15, 399(1-2): 91-95 (abstract).
Esposito, Giuseppe, et al.
Journal of Molecular Medicine. 2006 Mar, (abstract).
The therapeutic potential of cannabis
Baker, David, et al.
The Lancet Neurology. 2003 May, (abstract).
Amnesia induced by β-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade
Mazzola, Carmen, et al.
European Journal of Pharmacology. 2003 Sep 23, (abstract).